Nachrichten zur Zymeworks Inc. Aktie

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

…

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the…

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FR?-Targeting Antibody-Drug Conjugate

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…

Zymeworks: H.C. Wainwright begrüßt die strategische Neuausrichtung - Experten heben Kursziel an und sehen nun 85 % Potenzial

Zymeworks (ZYME) hat Anfang März 2026 einen entscheidenden Schritt zur langfristigen finanziellen Absicherung gemacht, indem das Unternehmen eine durch Lizenzgebühren…

Wer Biotechnologie-Aktien sucht, muss jetzt Zymeworks auf dem Schirm haben!

Zymeworks sollte man als Trader jetzt auf dem Schirm haben. Es handelt sich um ein biopharmazeutisches Unternehmen, das sich auf…

Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028

…

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

…

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma…

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.…

Zymeworks Outlines Strategic Priorities and Outlook for 2026

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

…

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of…

Stocks making the biggest moves premarket: Alphabet, Zymeworks, lithium producers, Quantum Computing, Clearwater Analytics and more

These are some of the stocks posting the largest moves in premarket trading.…

Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the…

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

…

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the…

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

…

Zymeworks Inc. 2024 Q4 - Results - Earnings Call Presentation

…

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the…

Ecor1 capital increases stake in Zymeworks with $1.88 million purchase By Investing.com

Ecor1 capital increases stake in Zymeworks with $1.88 million purchase…

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

…

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms…

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

…

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

dpa-AFX ProFeed